Related Experiment Video
Updated: Jun 1, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence
Piotr Jankowski1, Małgorzata Kloch-Badełek, Dorota Dębicka-Dąbrowska
1Department of Cardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland. piotrjankowski@interia.pl
Abstract:
The role of hypercholesterolemia as a risk factor for cardiovascular disease has been well-documented. Hypercholesterolemia is the most prevalent modifiable risk factor in Poland. Despite the fact that the benefits of cholesterol lowering have been known for a long time, the therapeutic goals recommended by guidelines are still often not attained in clinical practice. Only 3% of Poles with hypercholesterolemia achieve recommended cholesterol levels, and the rate of reaching recommended goals among patients receiving lipid-lowering drugs is low, approximately 30%. Control of hypercholesterolemia is not satisfactory also in patients with ischemic heart disease. The introduction of new statins, use of higher statin doses, and the evidence pointing to the effectiveness of combination therapy have provided us with effective tools whose broad application in everyday practice may lead to a significant improvement in the control of hypercholesterolemia in Poland.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures